Prandin: Rapid Postprandial Glucose Control for Type 2 Diabetes
Prandin
| Product dosage: 1mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.63 | $49.00 (0%) | 🛒 Add to cart |
| 60 | $1.45 | $98.00 $87.00 (11%) | 🛒 Add to cart |
| 90 | $1.39 | $147.00 $125.00 (15%) | 🛒 Add to cart |
| 120 | $1.36 | $196.00 $163.00 (17%) | 🛒 Add to cart |
| 180 | $1.33 | $294.00 $239.00 (19%) | 🛒 Add to cart |
| 270 | $1.31 | $441.00 $353.00 (20%) | 🛒 Add to cart |
| 360 | $1.29
Best per pill | $588.00 $466.00 (21%) | 🛒 Add to cart |
| Product dosage: 2mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.67 | $80.00 (0%) | 🛒 Add to cart |
| 60 | $2.50 | $160.00 $150.00 (6%) | 🛒 Add to cart |
| 90 | $2.46 | $240.00 $221.00 (8%) | 🛒 Add to cart |
| 120 | $2.42 | $320.00 $291.00 (9%) | 🛒 Add to cart |
| 180 | $2.41 | $480.00 $433.00 (10%) | 🛒 Add to cart |
| 270 | $2.38
Best per pill | $720.00 $643.00 (11%) | 🛒 Add to cart |
| 360 | $2.38 | $960.00 $858.00 (11%) | 🛒 Add to cart |
Synonyms | |||
Prandin (repaglinide) is a rapid-acting meglitinide-class oral antidiabetic agent indicated for the management of hyperglycemia in type 2 diabetes mellitus, particularly in patients with postprandial glucose excursions. It functions by stimulating insulin secretion from the pancreatic beta cells in a glucose-dependent manner, offering a targeted approach to mealtime glycemic control. Prandin is typically prescribed as an adjunct to diet and exercise and may be used as monotherapy or in combination with other antihyperglycemic agents like metformin when glycemic targets are not achieved with a single agent. Its unique pharmacokinetic profile allows for flexible dosing in relation to meals, making it a practical option for patients with irregular eating schedules.
Features
- Active Ingredient: Repaglinide
- Pharmacologic Class: Meglitinide derivative
- Mechanism of Action: Insulin secretagogue; closes ATP-dependent potassium channels in pancreatic beta-cell membranes
- Onset of Action: Within 30 minutes of oral administration
- Peak Plasma Concentration: Approximately 1 hour
- Elimination Half-Life: ~1 hour
- Dosage Forms: Oral tablets (0.5 mg, 1 mg, 2 mg)
- Administration: Preprandially (15–30 minutes before meals)
Benefits
- Provides rapid and short-lived insulin secretion, closely mimicking physiological postprandial insulin response
- Reduces postprandial glucose spikes effectively, contributing to lower HbA1c levels
- Offers dosing flexibility; can be taken with each main meal or omitted if a meal is skipped
- Lower risk of prolonged hypoglycemia compared to longer-acting secretagogues due to short half-life
- Suitable for patients with renal impairment (no dosage adjustment required in renal dysfunction)
- May be used in combination therapy with drugs like metformin for synergistic glycemic control
Common use
Prandin is primarily used in the management of type 2 diabetes mellitus in adult patients. It is particularly beneficial for individuals who experience significant postprandial hyperglycemia and those with irregular meal patterns. It is often prescribed when first-line agents like metformin are contraindicated or not tolerated, or as add-on therapy when monotherapy fails to achieve glycemic targets. It is not indicated for type 1 diabetes or diabetic ketoacidosis.
Dosage and direction
The recommended starting dose is 0.5 mg taken orally 15–30 minutes before each main meal. The dosage may be titrated at weekly intervals based on blood glucose monitoring, with increments of 0.5 mg or 1 mg preprandially. The maximum recommended single dose is 4 mg, and the maximum total daily dose should not exceed 16 mg. Dosing should be individualized; if a meal is skipped, the corresponding dose should be omitted to reduce hypoglycemia risk. Patients should be instructed to adhere to a regular meal pattern to optimize efficacy and safety.
Precautions
- Hypoglycemia is the most common adverse effect; patients should be educated on recognition and management
- Use with caution in patients with hepatic impairment; consider lower starting doses and careful titration
- Not recommended during pregnancy (Category C) unless potential benefit justifies potential risk
- May cause weight gain
- Periodic monitoring of liver function is advised
- Patients should be advised about the importance of regular blood glucose monitoring
- Concomitant use with other glucose-lowering agents may increase hypoglycemia risk
Contraindications
- Hypersensitivity to repaglinide or any component of the formulation
- Type 1 diabetes mellitus
- Diabetic ketoacidosis
- Concomitant use with gemfibrozil (strong CYP2C8 and OATP1B1 inhibitor) due to significantly increased repaglinide exposure and hypoglycemia risk
- Severe hepatic impairment
Possible side effect
- Hypoglycemia (most common)
- Upper respiratory tract infection
- Headache
- Diarrhea
- Arthralgia
- Back pain
- Nausea
- Constipation
- Weight gain
- Allergic skin reactions (rare)
- Elevated liver enzymes
Drug interaction
- Gemfibrozil: Contraindicated—increases repaglinide AUC by 8-fold
- CYP2C8 inhibitors (e.g., trimethoprim, clopidogrel): May increase repaglinide levels
- CYP2C8 inducers (e.g., rifampin): May decrease repaglinide efficacy
- Beta-blockers: May mask hypoglycemia symptoms
- NSAIDs, salicylates, sulfonamides, MAO inhibitors: May enhance hypoglycemic effect
- Thiazides, corticosteroids, thyroid products, sympathomimetics: May reduce hypoglycemic effect
Missed dose
If a dose is missed and the next meal is imminent, the missed dose should be skipped. The patient should take the next scheduled dose with the upcoming meal. Doubling the dose to compensate for a missed dose is not recommended due to increased hypoglycemia risk.
Overdose
Overdose may lead to severe hypoglycemia. Symptoms include confusion, tremors, sweating, palpitations, and loss of consciousness. Management includes immediate intake of oral carbohydrates (if conscious) or administration of intravenous glucose or glucagon. Close monitoring and supportive care are essential; hemodialysis is not effective due to high protein binding.
Storage
Store at controlled room temperature (20–25°C or 68–77°F). Keep in the original container, tightly closed, and protect from moisture and light. Keep out of reach of children. Do not use beyond the expiration date printed on the packaging.
Disclaimer
This information is intended for healthcare professionals and educated patients as a summary of key product characteristics. It does not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider for personalized recommendations and to discuss potential risks and benefits based on individual health status and concomitant medications.
Reviews
Clinical studies and post-marketing surveillance indicate that Prandin is effective in reducing postprandial glucose and HbA1c levels, with a safety profile consistent with its mechanism of action. Many patients appreciate the flexibility of mealtime dosing. However, hypoglycemia remains a concern, particularly during dose titration or with inconsistent carbohydrate intake. Healthcare providers generally regard it as a useful option for specific patient populations, especially those with prominent postprandial hyperglycemia or renal impairment. Long-term real-world evidence supports its role in individualized diabetes management strategies.